76 results
424B3
SRZN
Surrozen Inc
8 Nov 23
Prospectus supplement
4:27pm
number of the Company’s proprietary targets and to make, use, sell, offer for sale, import and exploit products incorporating the antibodies … technology and targets the Wnt-signaling pathway in the intestinal epithelium. In preclinical animal models of acute and chronic colitis, SZN-1326
8-K
EX-99.1
2e7c59obkv3yty5
8 Nov 23
Surrozen Provides Third Quarter 2023 Financial Results
4:09pm
424B3
44fb 0bb0k
9 Aug 23
Prospectus supplement
4:39pm
8-K
EX-99.1
4lh9zapgv p97w
9 Aug 23
Surrozen Provides Second Quarter 2023 Financial Results
4:16pm
424B3
ypa9ho7mxxzzkps06n7
10 May 23
Prospectus supplement
4:47pm
8-K
EX-99.1
o00uhbtso
10 May 23
Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates
4:14pm
424B3
9loh70
7 Apr 23
Prospectus supplement
5:20pm
424B3
ztu3bfwb
6 Apr 23
Prospectus supplement
5:15pm
POS AM
u8s7e qlqy85ins
31 Mar 23
Prospectus update (post-effective amendment)
4:52pm
POS AM
s3cpi 3sk
31 Mar 23
Prospectus update (post-effective amendment)
9:09am
424B5
kvd9esj4
21 Dec 22
Prospectus supplement for primary offering
6:05am